https://orcid.org/0000-0003-0809-8068
References
- Chou ST, Fasano RM. Management of patients with sickle cell disease using transfusion therapy: Guidelines and complications. Hematol Oncol Clin North Am. 2016 Jun;30(3):591–608. doi: 10.1016/j.hoc.2016.01.011
- Porter JB, Garbowski M. The pathophysiology of transfusional iron overload. Hematol Oncol Clin North Am. 2014 Aug;28(4):683–701. doi: 10.1016/j.hoc.2014.04.003
- Coates TD, Wood JC. How we manage iron overload in sickle cell patients. Br J Haematol. 2017 Jun;177(5):703–716. doi: 10.1111/bjh.14575
- Vichinsky EP, Ohene-Frempong K. Approaches to transfusion therapy and iron overload in patients with sickle cell disease: results of an international survey. Pediatr Hematol Oncol. 2011;28(1):37–42. doi: 10.3109/08880018.2010.505497
- Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331(9):567–573. doi: 10.1056/NEJM199409013310902
- Treadwell MJ, Law AW, Sung J, et al. Barriers to adherence of deferoxamine usage in sickle cell disease. Pediatr Blood Cancer. 2005;44(5):500–507. doi: 10.1002/pbc.20290
- Lobo C, Angulo IL, Aparicio LR, et al. Retrospective epidemiological study of Latin American patients with transfusional hemosiderosis: the first Latin American epidemiological study in iron overload–the RELATH study. Hematology. 2011;16(5):265–273. doi: 10.1179/102453311X13085644680302
- Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107(9):3455–3462. doi: 10.1182/blood-2005-08-3430
- Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91(7):873–880.
- Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2010;95(4):557–566. doi: 10.3324/haematol.2009.014696
- Pennell DJ, Porter JB, Cappellini MD, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with beta-thalassemia major. Haematologica. 2012;97(6):842–848. doi: 10.3324/haematol.2011.049957
- Meerpohl JJ, Schell LK, Rücker G, et al. Deferasirox for managing transfusional iron overload in people with sickle cell disease. Cochrane Database Syst Rev. 2014;5:CD007477.
- Vichinsky E, Bernaudin F, Forni GL, et al. Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol. 2011;154(3):387–397. doi: 10.1111/j.1365-2141.2011.08720.x
- Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136(3):501–508. doi: 10.1111/j.1365-2141.2006.06455.x
- Díaz-García JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, et al. Deferasirox nephrotoxicity-the knowns and unknowns. Nat Rev Nephrol. 2014;10(10):574–586. doi: 10.1038/nrneph.2014.121
- Danan G, Benichou C. Causality assessment of adverse reactions to drugs–I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46(11):1323–1330. doi: 10.1016/0895-4356(93)90101-6
- Braga CCB, Benites BD, de Albuquerque DM, et al. Deferasirox associated with liver failure and death in a sickle cell anemia patient homozygous for the -1774delG polymorphism in the Abcc2 gene. Clin Case Rep. 2017;5(8):1218–1221. doi: 10.1002/ccr3.1040
- Lee JW, Kang HJ, Choi JY, et al. Pharmacogenetic study of deferasirox, an iron chelating agent. PLoS One; 2013:8(5):e64114. doi: 10.1371/journal.pone.0064114